Digital Health Investment Weekly Report (Issue 175): Global Funding Highlights and Industry Updates
Carbyne
Emergency Medical Communication Platform
SiMa.ai
Machine Learning Technology Developer
Chai Discovery
Drug Discovery Platform Developer
METiS TechBio
AI-Driven Drug Formulation Developer
Ultromics
Cardiovascular Disease Diagnostic Tool Developer
01 Global Digital Health Investment and Financing Overview
Emergency Medical Communication Platform Carbyne Secures $100 Million in Funding
On July 31, emergency medical communication platform Carbyne secured $100 million in funding from investors including AT&T Ventures, Axon Enterprise, Cox Enterprises, and Global Medical Response. The funds will be used to further develop its cloud-native platform, which leverages artificial intelligence to help emergency responders act faster, gain clearer information, and make more confident decisions during emergencies.
Machine Learning Technology Developer SiMa.ai Secures $85 Million in Financing
On August 1, machine learning technology developer SiMa.ai secured $85 million in funding, led by Maverick Capital with continued participation from existing investors and new investor StepStone Group joining. The funds will be used to further develop SiMa.ai's physical artificial intelligence computing platform, which enables advanced AI capabilities to be widely applied across various industry sectors including medical imaging.
Chai Discovery, a drug discovery platform developer, secures $70 million in Series A funding
On August 6, Chai Discovery, a drug discovery platform developer, secured $70 million in Series A funding led by Menlo Ventures, with participation from Anthology Fund, Yosemite, and others. This round of financing brings the total funding to $100 million. The funds will be used to further develop the Chai platform, applying it to previously unreachable targets and bringing in selected partners.
METiS TechBio, an AI-driven drug formulation developer, secures 400 million yuan in Series D funding
On August 4, METiS TechBio, an AI-driven drug formulation developer, secured 400 million yuan in D-round financing led jointly by the Beijing Medical and Health Industry Investment Fund and the Daxing District Industrial Investment Fund. The funds will accelerate the advancement of several strategic priorities for METiS TechBio, including platform automation upgrades, progress on self-developed product pipelines, deepening international strategic cooperation, and the recruitment of high-end talent.
Echocardiography Company Ultromics Secures $55 Million in Series C Funding
On July 31, Ultromics, an echocardiography company, secured $55 million in Series C funding, co-led by L&G, Allegis Capital, and Lightrock, with continued support from Oxford Science Enterprises, GV, and participation from major U.S. healthcare systems including UCM Ventures, the venture capital arm of the University of Chicago Medicine. The funds will be used to address undiagnosed heart failure on a large scale, making early heart failure detection a standard part of cardiac care during echocardiogram examinations.
Mental and Physical Health Service Provider Positive Development Secures $51.5 Million in Series C Funding
On August 6, Positive Development, a provider of mental and physical health services, secured $51.5 million in Series C funding led by aMoon Fund, B Capital, and Flare Capital Partners, with participation from Healthworx and others. The funds will be used to expand the autism developmental treatment model, explore new and existing markets, invest in new health programs and state Medicaid partnerships, and advance its proprietary technology and AI platform to further develop its DRBI-based care model.
Pulimeng, a developer of absorbable polymer materials for medical use, secures nearly 300 million yuan in Series C financing
On August 1, Puli Meng, a developer of medical absorbable polymer materials, secured nearly 300 million yuan in a Series C funding round jointly invested by Yahu Investment, Huatai Zijin, Xingong Industrial Investment, and Rongzhen Investment. The funds will be used for product development and market promotion to strengthen its leading position in the biodegradable consumables field.
Mental Health Platform Unmind Secures $35 Million in Funding
On July 31, mental health platform Unmind secured $35 million in funding, led by TELUS Global Ventures, with participation from existing investors Project A, Felix Capital, and Sapphire Ventures. The funds will be used to support Unmind's continued expansion in the U.S., providing employees with therapy, advanced wellness tools, scientifically-backed content, and AI coaching, ultimately fostering healthier and more productive workplaces globally.
Lifbio, a professional service provider in biologic material production, secures hundreds of millions in B2 round financing
On August 6, Lif BioService, a professional service provider in biopolymer production, secured hundreds of millions of yuan in its Series B2 round of financing. The investment was led by Xinfengming Group with participation from GGV Capital, several existing shareholders, Guanzi Fund, Hongpu Fund, and Huagai Capital, among others. The funds will be used to expand production capacity, enhance product quality, and drive the development of the furan bio-based industry.
Mashiluo, a medical nutrition product R&D and sales company, secures over 100 million yuan in B+ round financing
On August 4, Masher Pharmaceuticals, a research and sales company specializing in medical nutrition products, secured an over RMB100 million B+ round of financing. The round was jointly led by industry investors Bailian Commerce Investment and Bailian Zhigao, with existing shareholders Hony Capital and Hongsheng Capital continuing to increase their investments. The proceeds from this round will mainly be used to strengthen ongoing R&D investment in core products, advance clinical trials, and further consolidate the company's leading position in both "clinical and consumer" scenarios.
Dental AI Platform Developer Trust AI Secures $6 Million in Seed Funding
On August 5, Trust AI, a developer of dental artificial intelligence platforms, secured $6 million in seed funding led by Wehrle Implant Immersion Center, Goetze Dental, and Rockwood Programs. The funds will be used to further develop the Trust AI platform, apply it to previously unreachable goals, and bring in selected partners.
PhnyX Lab, a Developer of AI Platforms for Life Sciences and Engineering, Secures $4 Million in Seed Funding
On August 4, PhnyX Lab, a developer of life sciences and engineering generative AI platforms, secured $4 million in seed funding led by SK Networks, with participation from several notable angel investors, including Aidan Gomez, co-founder and CEO of Cohere. The funds will be used to further develop PhnyX Lab's AI-driven solutions to redefine biopharmaceutical workflows.
XtalPi and DoveTree Forge a HKD 47 Billion AI Drug Discovery Collaboration
On August 5, XtalPi and DoveTree reached a pipeline cooperation agreement with a total order value of approximately HKD 47 billion (USD 5.99 billion), setting a new record for order scale in the artificial intelligence (AI) + robotics-driven drug discovery field. XtalPi and DoveTree have entered into collaboration on multiple innovative preclinical-stage large and small molecule drug assets and will conduct new drug research and development targeting a series of DoveTree-specified targets. DoveTree will hold exclusive global development and commercialization rights to the related drugs.
Sony Medical Collaborates with Siemens Healthineers
On August 6, Sony Medical collaborated with Siemens Healthineers to integrate Siemens' high-end angiography system ARTIS with Sony’s NUCLeUS audiovisual management platform. This combination provides seamless control of audiovisual data, intelligent video routing, secure content capture, and remote collaboration to meet the demand for advanced solutions in interventional radiology, cardiology, and other fields, aiming to enhance patient care standards and surgical efficiency.
Beiden Medical Collaborates with Wondfo Biotech to Advance the Upgrade of the Non-Public Healthcare Market
On August 6, Better Medical and Wondfo Biotech reached a cooperation to jointly promote the upgrading of the non-public medical market and tap into the billion-dollar blue ocean. As a leader in China's POCT industry, Wondfo Biotech has nine major technology platforms including immunoassay and electrochemistry, with a rich product line covering areas such as cardiovascular and cerebrovascular diseases and infectious diseases. Its products are sold in more than 150 countries and regions worldwide, ensuring that Wondfo Biotech's high-quality products can quickly and accurately reach non-public medical institutions. Wondfo Biotech's strong R&D capabilities and extensive product line will provide Better Medical's customers with more comprehensive and professional in vitro diagnostic solutions.
Ophthalmology Care Management Service Organization EyeSouth Partners Acquires Sunvera
On August 6, EyeSouth Partners, an ophthalmology care management services organization (MSO), acquired Sunvera Group, marking its first entry into the Michigan market. Sunvera has built a regional ophthalmology and optometry service provider platform that includes subspecialty doctors in retina, glaucoma, oculoplastics, and cornea. This collaboration expands EyeSouth's business footprint by adding 15 clinics and four ambulatory surgery centers (ASCs).
Cangnan County Shanhai Digital Technology Acquires YiHui Technology for 300 Million RMB
On August 5, through Shanhai Shuke, Cangnan State-owned Assets purchased YiHui Technology, a subsidiary of ThinkTank Medical, for 300 million RMB. This transaction aims to divest ThinkTank Medical's loss-making smart healthcare business, improve financial conditions, and focus resources on developing commercial intelligence business. YiHui Technology reported revenue of 111 million RMB from January to October 2024, with a net loss of 316 million RMB, significantly dragging down the company’s performance. After the completion of this transaction, the Cangnan County Finance Bureau will become the actual controlling entity of ThinkTank Medical.
Mental Health Telemedicine Provider Cerebral Acquires Resilience Lab
On August 5, Cerebral, a provider of remote mental health care services, acquired Resilience Lab, a mental health service provider known for its unique clinical development platform and outcome-focused care delivery. This acquisition creates a comprehensive mental health delivery system that addresses some of the industry’s biggest bottlenecks: the lack of consistent reporting of clinical outcomes in assessing behavioral health severity and the shortage of clinical workforce. The combined organization will focus on seamlessly integrating psychiatry and therapy within a single digital pathway, enabling prescribers and therapists to collaborate as a unified team.
Private Equity Firm Brightstar Capital Partners Acquires Analyte Health
On August 4, Brightstar Capital Partners, a private equity firm focused on investing in business services, industry, consumer goods, government services, and technology companies, acquired Analyte Health, an online medical solutions provider. With proprietary technology stack and a nationwide network of partner laboratories and physicians in China, Analyte offers an integrated experience ranging from clinical testing to virtual care and prescription fulfillment. The company has served millions of patients across the U.S. and continues to expand its service offerings in areas such as wellness, sexual health, and hormone therapy.
Healthcare Service Provider Nystrom & Associates Acquires Ellie Mental Health
On August 4, healthcare services provider Nystrom & Associates acquired Ellie Mental Health's operations in Minnesota. This acquisition created one of the largest behavioral health networks in the region, with the merged organization operating 84 locations across five states. The new company has approximately 1,600 clinicians and provides appointments for 1.4 million patients annually. Services include therapy, psychiatry, substance use treatment, and many specialized and innovative programs for individuals, couples, and families.
Medical Company Demetra Holding S.p.A. Acquires Spine Surgery Company OrthoFundamentals
On August 1, medical company Demetra Holding S.p.A. acquired spinal surgery firm OrthoFundamentals, LLC and simultaneously established its global spine division, Demetra Spine. This acquisition not only marks Demetra's official entry into the spinal surgery sector but also reflects the extension of its long-term strategy centered on "infection control + minimally invasive + sustainability" into more procedural fields.
Artery Network/Arterial Orange Industry Think Tank/China Renaissance/BGI Co-Win/Rock Health/Mobile Health News/Fierce Health, etc.
Share
Like
Tap to view